Summary
Several NHS hospitals in England are preparing to use a new AI-powered blood test to help assess women who may have womb cancer. The test, called PinPoint, uses machine learning to analyze blood markers and give a risk score. This could reduce the need for invasive checks like transvaginal ultrasounds and biopsies. Around 90,000 women are referred each year for possible womb cancer, but only about 10,000 are diagnosed. The test aims to quickly rule out low-risk patients and speed up care for those who need it most.
Main Impact
The biggest impact of this AI blood test is that it could spare about one in five referred women from needing uncomfortable and invasive procedures. That means roughly 18,000 women in England each year could avoid a transvaginal ultrasound scan. The test costs around £30 and gives doctors a clear risk score. This helps them decide who can be monitored in primary care and who needs urgent hospital checks. For women at very low risk, the test could provide peace of mind without the stress of further tests.
Key Details
What Happened
Several NHS trusts, including Mid Yorkshire NHS Teaching Trust and Leeds Teaching Hospitals NHS Trust, plan to use the PinPoint test for gynaecological and other cancers. The test was developed by Leeds-based company PinPoint Data Science. It uses machine learning to analyze around 30 markers in a blood sample. The test then classifies patients as low, elevated, or high risk. This score helps doctors decide the next steps within existing cancer referral pathways.
Important Numbers and Facts
Around 90,000 postmenopausal women in England are referred by GPs each year for heavy bleeding checks. About 10,000 women are diagnosed with womb cancer annually, and around 2,700 die from the disease. A trial involving 16,481 patients across Yorkshire found that about one in 10 women referred for heavy bleeding had cancer. The test correctly identified 99.1% of cancers as elevated or high risk. For women in the lowest-risk group, the test had a negative predictive value of 99.8%, meaning it very rarely missed a cancer.
Background and Context
Currently, women referred for possible womb cancer usually have a pelvic exam that includes a transvaginal ultrasound. This involves inserting a probe into the vagina to measure the womb lining. Many women find this uncomfortable or painful. If doctors still suspect cancer, patients may need a biopsy or a hysteroscopy, which is an exam of the inside of the womb. These procedures can be distressing, especially for women who do not have cancer. The PinPoint test is designed to identify very low-risk women before these invasive steps are taken. It could also reduce the number of GP visits needed to rule out cancer. Dr. Jacinta Walsh, a GP in West Yorkshire, said patients sometimes need up to six GP visits before cancer is ruled out. The test could shorten that process and free up time for other patients.
Public or Industry Reaction
Professor Sean Duffy, chief medical officer at PinPoint Data Science and a former NHS England national clinical director for cancer, said the test's main value is ruling out women at very low risk. Tracy Jackson, a consultant gynaecologist at Leeds Teaching Hospitals NHS Trust, said most women seen through the current referral route do not have cancer, but the investigations can be uncomfortable or distressing. She said the test could help clinicians triage patients before hospital-based checks. Cancer Research UK described the test as promising but said more research is needed to understand its benefits for patients and the NHS. Samantha Harrison, a spokesperson for the charity, said early detection saves lives, but patients are not currently being diagnosed quickly enough.
What This Means Going Forward
The PinPoint test could change how womb cancer is diagnosed in the NHS. If rolled out widely, it could reduce the number of invasive procedures and speed up diagnosis for high-risk patients. However, more evidence is needed to see how the test affects patient outcomes, referral decisions, and NHS diagnostic capacity. The test is part of a broader push to use AI in the NHS. Other recent AI deployments include the MEMORI system at Kent and Canterbury Hospital for infection risk assessment, an AI triage tool in the NHS App, and AI-powered chest X-ray tools for lung cancer. The government has committed £20 million to roll out AI chest X-ray tools to all NHS trusts by 2029. The PinPoint test could become another important tool in the NHS's effort to diagnose cancer earlier and more efficiently.
Final Take
The AI blood test for womb cancer is a promising step toward less invasive and faster diagnosis. It could spare thousands of women from uncomfortable procedures each year while helping doctors focus on those who need urgent care. But like all new technologies, it will need careful monitoring to ensure it works well in real-world settings. If successful, it could become a standard part of cancer care in the NHS.
Frequently Asked Questions
How does the PinPoint AI blood test work?
The test uses machine learning to analyze around 30 markers in a blood sample. It then gives a risk score that classifies a patient as low, elevated, or high risk for womb cancer. Doctors use this score to decide if a patient needs further tests or can be monitored in primary care.
How many women could benefit from this test?
Around 90,000 women are referred each year for possible womb cancer. The test could spare about one in five of them, or roughly 18,000 women, from needing a transvaginal ultrasound scan. It could also reduce the number of GP visits needed to rule out cancer.
Is the PinPoint test available across the NHS now?
Not yet. Several NHS trusts, including Mid Yorkshire NHS Teaching Trust and Leeds Teaching Hospitals NHS Trust, plan to use the test. But it is not yet available nationwide. More research is needed to understand its full benefits before wider rollout.
